Stanniocalcin-1 Hormone in Nonpreeclamptic and Preeclamptic Pregnancy : Clinical, Life-Style, and Genetic Modulators by Juhanson, Peeter et al.
Stanniocalcin-1 Hormone in Nonpreeclamptic and
Preeclamptic Pregnancy: Clinical, Life-Style, and
Genetic Modulators
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Eero Kajantie, Seppo Heinonen, and Maris Laan*
Context and Objectives: The study represents the first comprehensive analysis of Stanniocalcin-1
(STC1) hormone in human pregnancy, assessing clinical, lifestyle, and genetic determinants of
circulating STC1 at term.
Design, Setting, andParticipants:Participants includedwomenwith (n50) andwithout (n316)
preeclampsia (PE) at delivery, recruited in the REPROgrammed fetal and/or maternal METAbolism
(REPROMETA) study (2006–2011, Estonia).Genetic associationanalysis combinedPE cases (n597)
and controls (n  623) from the REPROMETA and Finnish Genetics of Preeclampsia Consortium
(2008–2011) studies.
Main Outcome Measure(s): Maternal postpartum plasma STC1 was measured by ELISA (n  366)
and placental STC1 gene expression by TaqMan quantitative RT-PCR (n  120). Genotyping was
performed using Sequenom MassArray.
Results: Significantly higher STC1 plasma level was measured for the PE (median, 1952 pg/mL;
1030–4284 pg/mL) comparedwith non-PE group (median, 1562 pg/mL; 423–3781 pg/mL; P 3.7
104, Mann-Whitney U test). Statistical significance was enhanced after adjustment for cofactors
(linear regression, P 1.8 106). STC1 measurements were negatively correlated with maternal
smoking. Prepregnancy body mass index had a positive correlation with STC1 only among PE
patients (r 0.45; P .001). The strongest genetic association with hormone concentrations was
detected forSTC1 singlenucleotidepolymorphisms rs3758089 (Callele:minorallele frequency, 5%;
linear regression:  249.2 pg/mL; P .014) and rs12678447 (G allele: minor allele frequency, 7%;
147.0pg/mL;P .082). rs12678447placental genotypeswere significantly associatedwith STC1
gene expression (P  .014). The REPROMETA/Finnish Genetics of Preeclampsia Consortium meta-
analysis suggested an increased risk to develop late-onset PE for the rs12678447 G allele carriers
(P  .05; odds ratio  1.38 [0.98–1.93]).
Conclusions: Increased STC1 hormone represents a hallmark of late-onset PE. STC1 gene variants
modulate placental gene expression and maternal hormone levels. (J Clin Endocrinol Metab 101:
4799–4807, 2016)
Stanniocalcin (STC) is a glycoprotein hormone thatwasinitially described as a regulator of calcium homeo-
stasis in teleost fish (1), released in response to elevated
serum calcium from the corpuscles of Stannius in kidneys.
The human counterpart, Stanniocalcin-1 (STC1) protein,
was described in 1995 (2, 3). Studies in mammals indi-
cated that STC1 (and its paralog STC2) exhibits high sim-
ilarity with its teleost ortholog and has also an important
role in regulating calcium and phosphate metabolism (4,
5). Compared with fish, the mammalian STC1 appears to
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be involved in more diverse physiological and autocrine/
paracrine functions. In female reproductive endocrinol-
ogy, STC1 modulates ovarian function (6, 7), implanta-
tion (8, 9), gestation, and lactation (6, 10–12). The
expression of ovarian STC1 increases 15-fold during mu-
rine gestation, it is further up-regulated in lactating mice,
and the circulating hormone reaches detectable threshold
only during pregnancy and lactation (6). Transgenic mice
overexpressing human STC1 exhibit reduced female re-
productive competence and severely postnatal dwarfism
(10). Overexpression of STC1 inhibits normal skeletal de-
velopment (13).
Despite considerable expression in thehumanplacenta,
there is little knowledge on STC1 in human gestation. In
vitro studies have associated STC1 expression to angio-
genesis (14) and remodeling of the spiral arteries within
the maternal uterus (15), processes crucial for developing
and maintaining normal pregnancy. Our seminal study
showed that human STC1 gene exhibits distinct placental
gestational dynamics (11). Its placental transcript levels
increase 5-fold between gestational days 40 and 140, peak
atmidpregnancy, and drop low at term. In termplacentas,
the STC1 gene expressionwas significantly higher in cases
of preeclampsia (PE), mainly originating from impaired
placental function.Apilot analysis in129women revealed
that the mothers with PE pregnancies were measured the
highest postpartum circulating STC1 levels. Genome-
wide association studies (GWAS) have associated genetic
variants near STC1 with multiple renal traits, estimated
glomerular filtration rate (eGFR) (16, 17), chronic kidney
disease (18), and serum urate concentrations (19). This is
consistent with the pathophysiology of PE, often accom-
panied with proteinuria and renal failure. Furthermore,
a recent study demonstrated that STC1 is a proteinase
inhibitor of the pregnancy-associated plasma protein
(PAPP)-A and PAPP-A2, modulating IGF signaling (12).
Both encodinggenes,PAPPAandPAPPA2, are among the
most highly expressed genes in the human placenta (20),
and their altered expressionhas been linked to PE (21, 22).
The current study aimed at the first comprehensive
analysis of STC1 hormone levels in human pregnancy at
term. Specific objectives were: 1) to determine clinical and
lifestyle-related covariates of circulating STC1 levels; 2) to
confirm the robustness of increased maternal STC1 con-
centration in PE cases; 3) to screen the STC1 gene for the
variants modulating maternal hormone concentration
and placental STC1 transcript levels; and finally 4) to test
the association of these single nucleotide polymorphisms
(SNPs) with the risk to develop PE. The study revealed
increased STC1 hormone as a hallmark of PE and identi-
fiedmaternal lifestyle and genetic variantsmodulating cir-
culating STC1 levels and, potentially, the risk to PE.
Materials and Methods
REPROgrammed fetal and/or maternal
METAbolism (RERPOMETA) study
The REPROMETA study was approved by the Ethics Re-
view Committee of Human Research of the University of
Tartu, Estonia (permissions no. 146/18, 27.02.2006; 150/33,
18.06.2006; 158/80, 26.03.2007; and 180/M-15, 23.03.2009),
and it was carried out in compliance with the Helsinki Declara-
tion. A written informed consent to participate in the study was
obtained from each family before recruitment. All study partic-
ipants were recruited and the study material was collected at the
Women’s Clinic of Tartu University Hospital, Estonia in 2006–
2011. All participants were of White European ancestry and
living in Estonia.
The REPROMETA study represents family trios (mother, fa-
ther, placenta) recruited before or shortly after delivery, and it
covers well-defined pregnancy outcomes at term. In the current
study, the analyzedREPROMETAstudy subjects (n366)were
stratified into 2 subgroups: pregnancies with PE (n  50) and
without PE (non-PE, n 316) (Table 1 and Supplemental Table
1). In case-control genetic association analysis, the PE groupwas
subdivided based on the disease onset, as early-onset PE (EO-PE)
and late-onset PE (LO-PE) cases tend to have different etiology
(23). If the first symptoms appeared before 34 gestationalweeks,
PEwas classified as EO-PE (n 25), and if the symptoms started
after 34 completed weeks, as LO-PE (n  25) (24). Non-PE
group was comprised of uncomplicated pregnancies with the
delivery of a normal birth weight newborn for its gestational age
(NORM) (10th–90th percentile; n  110), pregnancies with
newborns small for gestational age (SGA) (10th percentile; n
64) and large for gestational age (LGA) (90th percentile; n 
89), and pregnancies accompanied with gestational diabetes
mellitus (GDM) (n 53). Details for clinical criteria applied for
PE (25), GDM (26), and SGA and LGA (27) are provided in
Supplemental Methods. Information on maternal smoking, so-
matometric data, and reproductive history was obtained from
self-reported questionnaires and medical records.
Quantitative genetic association analysis with STC1 hormone
levels was performed with the maternal (blood samples) and pla-
cental genotypes of the full REPROMETA sample set (n  366).
Case-controlassociation testing included thePEgroup(n50)and
controls representing normal pregnancy with normal birth weight
newborn, NORM group (n 110) (Table 1).
Human Molecular Genetics Research Group (P.J., K.R., T.K., M.L.), Institute of Molecular and Cell Biology, University of Tartu, Tartu 51010, Estonia; Department of Obstetrics and
Gynaecology (K.R., P.V.), University of Tartu, andWomen’s Clinic of Tartu University Hospital (K.R., P.V.), Tartu 51014, Estonia; Medical and Clinical Genetics (H.L.), University of Helsinki
andHelsinki UniversityHospital, and Institute forMolecularMedicine Finland (H.L.), University ofHelsinki, FIN-00014Helsinki, Finland;Obstetrics andGynecology (H.L., S.H.) andChildren’s
Hospital (E.K.), Helsinki University Hospital and University of Helsinki, FIN-00029 Helsinki, Finland; Chronic Disease Prevention Unit (E.K.), National Institute for Health and Welfare,
FIN-00271 Helsinki, Finland; Research Unit of Pediatrics, Pediatric Neurology, Pediatric Surgery, Child Psychiatry, Dermatology, Clinical Genetics, Obstetrics and Gynecology, Otorhino-
laryngology, Ophtalmology (E.K.), Medical Research Center Oulu, Oulu University Hospital and University of Oulu, FIN-90014 Oulu, Finland; and Institute of Biomedicine and Translational
Medicine (M.L.), University of Tartu, Tartu 50411, Estonia
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Finnish Genetics of Preeclampsia Consortium
(FINNPEC) study
Finnish PE patient and non-PE control samples originate from
the FINNPEC study cohort and the Southern Finland PE study
cohort. The study protocol was approved by the coordinating Eth-
ics Committee of the Hospital District of Helsinki and Uusimaa.
The FINNPEC study participants have been recruited in 5 univer-
sity centers in Finland (Helsinki, Turku, Tampere, Kuopio, and
Oulu) in 2008–2011. All participants were ofWhite European an-
cestry and living in Finland. All subjects provided a written in-
formed consent. Details of the FINNPEC study cohort are pub-
lished elsewhere (28, 29). In the current genetic case-control study,
the FINNPEC participants meeting the REPROMETA diagnostic
criteria for PE and NORM groups (non-PE pregnancy with a nor-
malbirthweightnewborn)were included(SupplementalMethods).
Identically to the REPROMETA study, the FINNPEC PE patients
were further subdivided into early-onset (EO-PE) and late-onset
(LO-PE) disease groups.
In total, there were 547 FINNPEC patients with PE (EO-PE,
n  165; LO-PE, n  382) and 513 controls. For 378 patients
(EO-PE, n  88; LO-PE, n  290) and 496 controls, also fetal
DNA was extracted from umbilical cord blood, and genotype/
phenotype association was analyzed (Supplemental Table 2).
Measurement of STC1 protein expression in
maternal plasma by ELISA
Plasma STC1 levels in 366 REPROMETA study participants
were analyzed using ELISA implemented by DuoSet ELISA kit
(DY2958; R&D Systems). The analyzed maternal postpartum
plasma samples were collected on the day of delivery, aliquoted,
and immediately stored at 80°C. The exact recorded time of
blood sampling was available for 88 samples, and the median
interval from the delivery to blood sampling was 2 hours and 21
minutes. Before ELISA analysis, the samples were thawed on ice
andprocessedwith STC1ELISAkit according tomanufacturer’s
protocol. The detailed ELISA workflow is described elsewhere
(11). All the measurements were performed in duplicate, and
every assayplate includeda reference sample for intra-assay vari-
ability estimation. In this experiment, the average intra-assay
variability for processed 10 ELISA plates was 4%and interassay
variability 7% accordingly.
Genotyping of the STC1 gene
Single nucleotide polymorphisms tagging the allelic associa-
tion structure of STC1 (tag-SNPs) were identified based on the
genotype data derived from the 1000 Genomes Project (http://
www.internationalgenome.org/) for UTAH residents with
Northern andWestern European ancestry (CEU) as an input for
Haploview Tagger software (version 4.2) (30). Tag-SNPs were
determined for the genic (12 893 bp) and 2672 bp of the 5
upstream regions, including gene promoter. The selected 13 tag-
SNPs and 22 captured SNPs (r2 0.9) are listed in Supplemental
Figure 1. One of the selected SNPs, rs3758086, is in strong link-
age disequilibrium (LD) (r2  0.9) with rs10109414 and
rs17786744 located 38.8 and 64.7 kb upstream of STC1 and
associated in GWAS with eGFR and serum urate levels, respec-
tively (17, 19).
Genomic DNA extracted from REPROMETA maternal
blood samples was genotyped for 13 SNPs (n 366) (Table 1).
REPROMETA placental DNA (n 366) and FINNPEC sam-
ples (maternal blood, n  1060; umbilical cord blood DNA,
n  874) (Supplemental Table 2) were genotyped for 3 SNPs
(rs12678447, rs3758089, rs3758086). SNPgenotypingwasper-
formed on SequenomMassArray platform (Sequenom) accord-
ing to standard protocol (SupplementalMethods, Supplemental
Table 3).
Placental gene expression of the STC1 gene
Expressionof theSTC1gene in theplacentawasassessedwith
TaqMan quantitative RT-PCR (RT-qPCR) assay for a subset of
placental samples from the REPROMETA study subjects (n 
120). Placentas (stored at4°C)hadbeen sampledwithin1hour
after vaginal delivery or Caesarean section (C-section). Details
for placental sampling, RNA extraction, cDNA synthesis, and
qPCR are provided in Supplemental Methods. The assays of the
target gene STC1 (TaqMan ID 4331182) and reference gene
ubiquitinC (UBC) (ID4448484)were amplified in abiplexPCR.
Relative STC1 placental mRNA expression values were deter-
Table 1. Parental and Offspring Characteristics of the Analyzed REPROMETA Study Groups
Parameter PE (n  50) Non-PE (n  316) NORM (n  110)
Maternal age (y) 27.9 	 6.0 28.8 	 5.9 28.3 	 5.4
Prepregnancy BMI (kg/m2) 24.4 	 4.8 24.4 	 5.3 23.5 	 4.4
Nulliparity (n) 34 (68%) 136 (43%)a 48 (44%)a
Gestational age at birth (d) 245.2 	 23.1 278.1 	 12.3a 278.9 	 12.9a
Newborn weight (g) 2198.1 	 792.8 3790.5 	 931.8a 3640.8 	 519.5a
Newborn length (cm) 44.6 	 4.6 50.8 	 3.4a 50.8 	 2.2a
Ponderal index (g/cm3) 2.44 	 0.29 2.82 	 0.33a 2.76 	 0.25a
Gender (male/female) 23/27 160/156 59/51
Gestational weight gain (kg) 14.9 	 6.0 15.9 	 6.5 15.3 	 7.5
Smokers during pregnancy (n) 6 (12%) 59 (19%) 17 (15%)
Delivery mode (vaginal/C-section) 9/41 200/116a 97/13a
Placental weight (g) 402.7 	 121.4 621.4 	 180.8a 571.5 	 117.0a
Data given as mean 	 SD, except where indicated differently. Nulliparity, no previous childbirth; ponderal index, a ratio of body weight to length;
non-PE, study group comprised of uncomplicated pregnancies with the delivery of NORM, SGA (10th percentile), or LGA (90th percentile) and
pregnancies accompanied with GDM; NORM, a subset of non-PE group. Details on the SGA, LGA, and GDM subgroups are provided in
Supplemental Table 1.
a P  .05 compared with PE group, Student’s t test (for quantitative variables) or 2 test (for binary variables).
doi: 10.1210/jc.2016-1873 press.endocrine.org/journal/jcem 4801
mined by comparative cycle of threshold (CT) method that ac-
counted for mean values of normalized expression calculated by
averaging 3 independentlymeasured normalized expression val-
ues of the triplicate. Q-Gene software was used for calculations
and efficiency corrections (31).
Statistical analysis
Covariates modulating maternal hormone levels were as-
sessedusingunivariate analysis betweenELISAmeasurements of
STC1 and clinical/lifestyle parameters of REPROMETA sub-
groups of PE (n 50) and non-PE (n 316) cases. The analyzed
parameters included maternal age, prepregnancy body mass in-
dex (BMI), parity, gestational weight gain and smoking status,
gestational age, placental weight and delivery mode, newborn
gender, and birth weight/length. Statistical significance thresh-
old after correction for the number of independent traits was
estimated   0.05/8  6.25  103.
All genetic tests were implemented in PLINK software, version
1.07(32).GeneticassociationanalysisbetweenREPROMETAma-
ternal postpartumSTC1measurements andmaternal/placental ge-
notypes (n 366) was performed using linear regression analysis.
The tests applied additive geneticmodel andwere adjusted for pre-
determined covariates for circulating STC1 levels. All genetic asso-
ciation tests used natural logarithm transformed STC1 hormone
ELISA measurements. Association of studied SNPs with the pla-
cental STC1 gene expression level was tested using REPROMETA
placenta samples (n  120). Linear regression analysis was per-
formed for logarithm transformed relative mRNA values and ge-
notypes of the STC1 genic SNPs, adjusted by the study group and
delivery mode. Case-control analysis comparing PE patients and
NORMinREPROMETAandFINNPEC studies for STC1 genetic
variantswasassessedby logistic regressionadditivemodel,adjusted
for maternal age, BMI, and parity as known risk factors for PE
development (33). Analysis of the FINNPEC study data was addi-
tionally adjusted for the recruitment center. The results of the
REPROMETAand the FINNPECcase-control analysiswere com-
bined in a meta-analysis under fixed effects model implemented in
PLINK software. For SNP-STC1 hormone analysis, the stringent
Bonferroni threshold was calculated  0.05/13 (SNPs) 3.8
103, and for SNP-gene expression and case-control association
testing 0.05/3 1.67 102.
Results
Elevated maternal postpartum plasma STC1 in PE
In theREPROMETAstudy sample, significantly higher
STC1 postpartum plasma level was measured in pregnan-
cies complicated with PE (n 50) compared with non-PE
women (n  316). Median STC1 was measured 1952
pg/mL in the PEgroup (range, 1030–4284pg/mL; n50)
and 1562 pg/mL in non-PE group (range, 423–3781 pg/
mL; n  316) (P  3.7  104, Mann-Whitney U test;
significant after Bonferroni correction) (Figure 1A).
Across all study subjects, a significantly higher median
STC1 levelwasdetected for themotherswhogavebirthwith
normal vaginal delivery compared with C-section (median,
1663.5 vs 1446 pg/mL; P  .013) (Figure 1B). Notably,
STC1 was reduced among mothers who smoked during
pregnancy compared with nonsmokers (1385 vs 1631 pg/
mL; P  .02). Trends for higher STC1 levels among preg-
nancieswith female comparedwithmalenewborns (1656vs
1492pg/mL;P .053)andincaseswithmaternalnulliparity
(1662vs1524pg/mL;P .074)wereobserved (Supplemen-
tal Figure 2, A and B). The prepregnancy BMI had a signif-
icant positive correlationwith circulating STC1 only among
PE patients (r 0.45; P .001, significant after Bonferroni
correction), whereas women in the non-PE group showed a
trend for reduced STC1 with increasing maternal age (P 
.050) (Figure 1C). We were unable to find any statistically
supported associations between maternal postpartum
plasma STC1measurements and gestational age at delivery,
time of postpartum blood draw (within 24 h), placental
weight, gestational weight gain, and newborn’s anthropo-
metric measurements at birth (Supplemental Figures 2, C–I,
and 3).
Notably, when the identified clinical and lifestyle-related
cofactors were incorporated into the analysis, statistical sig-
nificance of the association of higher STC1 plasma levels in
PE compared with non-PE pregnancies was enhanced by 2
orders ofmagnitude.The comparisonof circulating STC1 in
the 2 groups adjusted for delivery mode, smoking status,
maternal age, and prepregnancy BMI resulted in highly sig-
nificant difference (linear regression,  500.8 pg/mL; P
1.8 106) (Figure 1A).
Genetic modulators of circulating STC1 hormone
level
In order to assess potential genetic modulators of
circulating STC1, we tested association between genetic
variants in the STC1 gene and hormone levels in ma-
ternal plasma of the REPROMETA participants (n 
366). From among the 13 analyzed tag-SNPs, the stron-
gest genetic association was detected for 2 rare variants,
rs3758089 (C allele: minor allele frequency [MAF],
5%) and rs12678447 (G allele: MAF 7%) (Table 2).
SNP rs3758089, located approximately 1.2 kb up-
stream of the STC1 gene transcription start site, exhib-
ited the largest allelic effect (linear regression, 249.2
pg/mL; P  .015). Minor allele carriers of both rare
SNPs had significantly higher median STC1 levels com-
pared with wild-type homozygotes (Mann-Whitney U
test; P  .05), rs3758089 CT/CC-compared TT-geno-
type carriers 1915.5 vs 1576 pg/mL and rs12678447
GA/GG-compared with AA-group 1873 vs 1562 pg/
mL, respectively (Figure 2A).
None of the common SNPs in the STC1 gene exhibited a
statistically significant effect on circulating STC1 levels (Ta-
ble 2 and Supplemental Table 4). A trend towards associa-
tion was observed for rs3758086 (T allele:MAF, 46%) and
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rs423432 (Aallele:MAF,48%). SNPrs3758086 is in strong
LDwithareportedGWAShitsrs10109414andrs17786744
(r20.9; at38-kbdistance) for renal functionparameters,
eGFR, and serum urate concentration (17, 19) (Supplemen-
tal Figure 1).
Because the STC1 gene is also expressed in the placenta
(11), we assessed whether the composition of placental
genotypes may further modulate maternal circulating
STC1 levels. Three SNPs (rs12678447, rs3758089,
rs3758086) highlighted in the analysis of maternal geno-
type-STC1hormone associations (Table 2)were addition-
ally genotyped for the respective placental DNA samples
(n  366). None of the analyzed associations between
placental genotypesandmaternalhormonemeasurements
reached statistical significance.
Genetics of placental expression of the STC1 gene
In the analysis of potential covariates for the placen-
tal STC1 gene expression at term, none of the tested
parameters appeared to have a major effect (Supple-
mental Figure 4, A–N). We analyzed whether the SNPs
highlighted in the association testing with plasma
STC1 hormone levels may also represent genetic mod-
ulators of STC1 transcript levels. Correlation between
STC1 mRNA expression and genotype data of 2 rare
(rs12678447, rs3758089) and 1 common SNP
(rs3758086) was tested for 120 placental samples. The
strongest association was detected for the rare variant
rs12678447 (linear regression, P .014; significant after
Bonferroni correction) (Table 2 and Figure 2B). Also, the
other tested SNPs showed a trend for association (P .07)
and the same direction of effects as in previous analysis
with the hormone level. We conclude that the highlighted
SNPs indeed represent functional variants with the direct
effect on placental expression of the STC1 gene. The ge-
netic effects in the placenta are consistent with the asso-
ciations identified betweenmaternal genotypes and circu-
lating hormone levels.
Figure 1. Maternal postpartum plasma STC1 hormone levels in the REPROMETA study sample subgrouped based on (A) the pregnancy outcome,
(B) delivery mode and smoking status, and (C) maternal age and prepregnancy BMI. The boxes represent the 25th and 75th percentiles; median is
denoted as the line that bisects the boxes. The whiskers are lines extending from each end of the box covering the extent of the data on 1.5x
interquartile range; circles represent the outlier values. Statistical significance in comparisons of median STC1 values among groups was tested
with Mann-Whitney U test (MW). Additionally, linear regression (LR) model was applied to adjust for the delivery mode, smoking status, maternal
age, and prepregnancy BMI as covariates. Associations between STC1 and maternal age and prepregnancy BMI were assessed with LR. Regression
line was plotted separately for PE (n  50, discontinuous line) and non-PE (n  316, continuous line) study groups, respectively. non-PE, all
pregnancies without PE.
doi: 10.1210/jc.2016-1873 press.endocrine.org/journal/jcem 4803
STC1 genetic variants and risk to develop PE
We hypothesized that STC1 gene variants modulating
gene expression and circulating STC1hormone levelsmay
also represent risk factor for PE. Because PE arises from
the malfunction of the mother and placenta, the condu-
cted case-control study targeted both, maternal and
fetal genotypes of STC1 rare variants rs12678447 and
rs3758089, as well as a common variant rs3758086. Due
to limited size of the REPROMETA patient groups rep-
resenting PE (n  50) and NORM (n  110), this pilot
case-control genetic association study included addition-
ally respective cases/controls (PE, n  547; NORM, n 
513) from the FINNPEC study.
No associations from case-control genetic tests remained
statistically significant after correction for multiple testing
(Table 3). Still, meta-analysis across REPROMETA and
FINNPEC data suggested an increased risk to develop
LO-PE for the carriers of rs12678447 G allele (P  .05;
OR  1.38). Frequency of this variant in both,
REPROMETA and FINNPEC, PE groups was 10%,
whereas allele frequencies between 2 studies differed for the
controls. In REPROMETANORMgroup, the rs12678447
Gallelewas 6.4%andFINNPECNORMgroup 8.8%.The
latter is somewhat higher compared with ENSMBL data-
base, where prevalence of this variant among Finns is 7.6%
and in other reported European populations 1.0%–4.7%.
In REPROMETA, also 2 other tested
SNPs resulted in association results
with LO-PE, supported by nominal
P .05.
We did not identify any signifi-
cant associations betweenmaternal
STC1 genetic variants and the on-
set EO-PE (Table 3). Fetal STC1
allelic composition, determined
from the placental tissue (REPRO-
META) or umbilical cord blood
(FINNPEC) genomic DNA, did not
show any associations with mater-
nal risk to develop PE in neither of
the study samples nor meta-analy-
sis (Supplemental Table 5).
Discussion
We conducted the first systematic
analysis measuring circulating STC1
Figure 2. Genetic effects of the STC1 gene polymorphisms in the REPROMETA study sample
shown for (A) the maternal genomic variants on maternal plasma STC1 level and (B) the placental
genomic variants on placental STC1 gene expression. STC1 hormone levels in maternal plasma
were measured using ELISA (DY2958; R&D Systems). Placental gene expression levels were
determined using TaqMan RT-qPCR (assay ID 4331182). Boxes represent the 25th and 75th
percentiles; median is denoted as the line that bisects the boxes. The whiskers are lines extending
from each end of the box covering the extent of the data on 1.5x interquartile range; circles
represent the outlier values. Statistical significance between the minor allele carriers and major
allele homozygotes was tested using Mann-Whitney U test (MW) comparing median values of
the distributions. In parallel, linear regression (LR) analysis was applied to adjust for possible
confounding factors. Testing associations between genetic variants and circulating STC1
hormone levels were adjusted by the study group (PE or non-PE), delivery mode, maternal age,
smoking status, and prepregnancy BMI. SNP gene expression association tests were adjusted for
the study group and delivery mode.
Table 2. Genetic Association Tests for the Maternal Circulating STC1 Hormone and Placental STC1 Gene
Expression Levels
Genotyped
Samples Analyzed Phenotype Unit
rs12678447 (A/G) rs3758089 (T/C) rs3758086 (C/T)
MAF (%)
P Value,
 (SE) MAF (%)
P Value,
 (SE) MAF (%)
P Value,
 (SE)
REPROMETA
mothers
Maternal STC1 hormone
(n  366)
pg/mL 7.0 8.23  102 5.0 1.47  102 46.0 1.48  101
147.0 (82.8) 249.2 (97.2) 58.6 (41.8)
REPROMETA
placentas
Maternal STC1 hormone pg/mL 7.0 8.74  101 4.0 2.38  101 43.0 1.28  101
(n  366) 12.8 (82.9) 128.9 (107.6) 60.2 (40.7)
Placental STC1 mRNA
expression (n  120)
log2 (RGE) 6.0 1.39  102* 4.0 6.67  102 47.0 6.14  102
0.80 (0.32) 0.72 (0.39) 0.27 (0.15)
STC1 hormone levels in maternal plasma were measured using ELISA (DY2958; R&D Systems). Placental gene expression levels were determined
using TaqMan RT-qPCR (assay ID 4331182). Statistical significance in SNP-trait association testing was assessed using linear regression additive
model. In the table heading, the tested alleles for each SNP are shown as underlined in bold. Association testing between maternal or placental
genotypes and maternal STC1 hormone levels were adjusted for the identified cofactors (Figure 1 and Supplemental Figure 2): study group (PE or
non-PE), delivery mode (vaginal or C-section), smoking status, maternal age, and prepregnancy BMI. Association tests between placental
genotypes and gene expression were adjusted for the group and delivery mode. Statistically significant nominal P values are highlighted in bold,
and significant results after Bonferroni correction for multiple testing are indicated with an asterisk. RGE, relative gene expression.
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concentrations in human postpartum plasma and assess-
ing the modulatory effect of maternal, fetal and genetic
determinants. The analysis confirmed a robust and statis-
tically highly significant association of increasedmaternal
hormone levels with the diagnosis of PE (P 1.8 106;
linear regression adjusted for cofactors). In PE compared
with non-PE cases, the median measured STC1 level was
approximately 25% higher and a significant positive cor-
relation was detected with maternal BMI. The exact roles
of STC1 in pregnancy and in the pathogenesis of PE are
largely unknown. STC1 was reported to inhibit the pro-
teolytic activity of PAPP-A and PAPP-A2 in vitro (12).
Reduced maternal serum PAPP-A levels refer to a high PE
risk (21),whereasmaternal sera andplacental tissues from
PE cases show, in contrast, elevated levels of PAPP-A2
(22). We speculate that increased circulating STC1 in PE
pregnancy may represent a feedback mechanism to high
expression of PAPP-A2. A study in mice showed that
PAPP-A represents a pregnancy-associated oncogene,
whereby the high expression of STC1 (and STC2) in the
mammary glands during late pregnancy and lactation cor-
related with the reduced PAPP-A activity and a protective
effect against carcinogenesis (34).
Interestingly, STC1measurementswere negatively cor-
related with maternal smoking. Because a decreased risk
of PE occurrence among smoking pregnant women has
been shown (35), it is consistent with lower concentration
of STC1 detected in the non-PE group. Reduced STC1 in
smokersmay either reflect the overall effect of smoking on
gestational metabolism and/or be involved in the PE pro-
tective effect.
As a second study outcome, we identified genetic vari-
ants affecting the expressionof the STC1 gene.Weapplied
2 independent genetic analyses, testing the association of
maternal genotypes with measured interindividual varia-
tion in STC1 hormone levels and testing the association of
placental genotypes with term placental STC1 transcript
abundance. The analysis highlighted concordant results
for 2 rare SNPs (rs3758089; MAF, 5% and rs12678447;
MAF, 7%) with the effect on STC1 gene expression and
maternal hormone levels (Table 2 and Figure 2). SNP
rs3758089 is located in the STC1 promoter region and
less than 200 bp from a strong H3K27Ac peak (a land-
mark for a regulatory element) identified in the Encyclo-
pedia of DNAElements (ENCODE) project (36). Because
rs12678447 in the third intron of the STC1 gene is par-
tially in LD with rs3758089 (Supplemental Figure 1), we
suggest that the causative, gene expression modulating
variant is rather the latter. The study detected a trend for
the association for a common variant rs3758086 (2.7 kb
upstream from STC1 transcription start site) with mater-
nal hormone and placental STC1 gene expression. This
SNP is in strong LDwith 2 GWAS hits for renal function-
related parameters, located in distance 38–65 kb (r2 
0.9; rs10109414 and rs17786744). The role of our dis-
covered variants in the STC1 genomic region, rare SNPs
Table 3. Case-Control Association Analysis Between STC1 Genetic Variants and PE in REPROMETA and FINNPEC
Studies
Analysis
Group
Phenotype n,
Case/Control
rs12678447 (A/G) rs3758089 (T/C) rs3758086 (C/T)
MAF (%)
Case/
Control
P Value (OR)
[95% CI]
MAF (%)
Case/
Control
P Value (OR)
[95% CI]
MAF (%)
Case/
Control
P Value (OR)
[95% CI]
REPROMETA mothers PE 9.0/6.4 5.14  102 (2.80) 7.0/3.6 1.28  102 (4.70) 38.0/47.0 1.24  101 (0.67)
n  50/110 [0.99–7.85] [1.39–15.96] [0.40–1.11]
EO-PE 8.3/6.4 2.42  101 (2.24) 6.0/3.6 8.98  102 (4.00) 46.0/47.0 6.75  101 (0.87)
n  25/110 [0.58–8.63] [0.80–19.88] [0.46–1.65]
LO-PE 10.0/6.4 1.05  101 (2.86) 8.0/3.6 4.11  102 (4.54) 30.0/47.0 2.13  102 (0.44)
n  25/110 [0.80–10.20] [1.06–19.41] [0.21–0.88]
FINNPEC mothers PE 9.0/8.8 4.29  101 (1.14) 5.5/5.0 3.87  101 (1.19) 43.0/45.0 3.12  101 (0.90)
n  547/513 [0.82–1.56] [0.80–1.80] [0.75–1.10]
EO-PE 7.5/8.8 6.67  101 (0.90) 5.0/5.0 7.34  101 (1.11) 42.0/45.0 2.26  101 (0.84)
n  165/513 [0.55–1.46] [0.61–2.00] [0.64–1.11]
LO-PE 10.0/8.8 1.29  101 (1.31) 6.0/5.0 2.65  101 (1.28) 44.0/45.0 3.21  101 (0.90)
n  382/513 [0.92–1.85] [0.82–2.01] [0.73–1.10]
Meta-analysis PE n.a. 1.82  101 (1.23) n.a. 1.08  101 (1.37) n.a. 1.38  101 (0.87)
n  597/623 [0.90–1.67] [0.93–2.02] [0.73–1.04]
EO-PE n.a. 9.92  101 (0.99) n.a. 3.64  101 (1.30) n.a. 2.01  101 (0.85)
n  190/623 [0.63–1.57] [0.74–2.25] [0.66–1.09]
LO-PE n.a. 5.86  102 (1.38) n.a. 9.60  102 (1.43) n.a. 1.10  101 (0.85)
n  407/623 [0.98–1.93] [0.93–2.19] [0.70–1.03]
Case-control association testing was performed using logistic regression additive model, adjusted for maternal age, BMI, and parity in in both
studies. In FINNPEC analysis, recruitment center was included as an additional cofactor. P values for meta-analysis are combined under fixed effects
model. In the table heading, the tested alleles for each SNP are shown as underlined in bold. Statistically significant nominal P values are indicated
in bold, .05  P  .1 are underlined. n.a., not applicable.
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rs3758089 and rs12678447 in relation to the kidney func-
tion is still to be analyzed.
We performed a pilot case-control association testing
of the identified STC1 regulatory SNPs for the risk to
develop PE. Although no robustly supported statistically
significant associations we detected, the observed trends
for the STC1 variants as potential genetic risk factors for
LO-PE warrant further investigations. Differently from
EO-PE, which is considered to arise primarily due im-
paired placental development (23), LO-PE develops at the
third trimester due to the limited capacity of maternal
metabolism to copewith theneeds of the growingplacenta
and fetus (37, 38). The pathophysiology of PE involves
various mechanisms being strongly implicated by renal
dysfunction and renin angiotensin system (14, 15, 39).We
hypothesize that elevated STC1 level during LO-PEmight
act as a compensatorymechanism to impair renal function
and in some degree it might be modulated by the STC1
genetic variants. Previous experiments with STC1 trans-
genic mice suggest that STC1 acts as a potent antiinflam-
matory and renal protective protein (40).
Regarding the study limitations, we consider modest
sample size as an issue in our genetic analyses. Because the
original REPROMETA study design was based on the
recruitment at the delivery room, thematernal blood sam-
ples were drawn within 24 hours postpartum. However,
the exact interval from the delivery to blood draw was
available only for a subset of cases. The gestational and
postpartum dynamics of STC1 hormone, and the respec-
tive modulatory factors are still to be investigated in pro-
spective studies.
In summary, our comprehensive analysis of pregnancy-
related effectors of STC1 in human gestation at term re-
vealed a substantially increased hormone levels in PE pa-
tients. The analysis of tag-SNPs representing the STC1
genic region discovered genetic variants modulating pla-
cental gene expression and maternal hormone levels.
These SNPs have a potential to be further investigated as
risk factors for LO-PE and for impaired renal function.
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